Detail akcie Invion online

Business Summary: Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.
Financial Summary: BRIEF: For the six months ended 31 December 2019, Invion Ltd revenues increased 58% to A$1.9M. Net loss decreased 11% to A$1.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Depreciation and amortisation expenses decrease of 82% to A$139K (expense), Administration and corporate expense decrease of 26% to A$475K (expense).